GEICAM/2014-12 (FLIPPER) study: First analysis from a randomized phase II trial of fulvestrant (F)/palbociclib (P) versus (vs) F/placebo (PL) as first-line therapy in postmenopausal women with HR (hormone receptor)+/HER2-endocrine sensitive advanced breast cancer (ABC)
No Thumbnail Available
Identifiers
Date
2020-09-01
Authors
Albanell, J.
Martinez, M. T. M.
Ramos, M.
O'Connor, M.
De la Cruz-Merino, L.
Santaballa Bertran, A.
Martinez-Janez, N.
Moreno, F.
Fernandez Perez, I.
Alarcon Company, J.
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Metrics
Export
